8-K: Quipt Home Medical to be Acquired for US$3.65 Per Share

Quipt Home Medical Corp. has entered into a definitive agreement to be acquired by affiliates of Kingswood Capital Management and Forager Capital Management for US$3.65 per share in an all-cash transaction.

Summary

• Quipt Home Medical Corp. (Quipt) will be acquired by 1567208 B.C. LTD and REM Aggregator, LLC (Purchasers), entities affiliated with Kingswood Capital Management, LP (Kingswood) and Forager Capital Management, LLC (Forager).
• The acquisition price is US$3.65 per common share in cash.
• The transaction values Quipt at approximately US$260 million, including Quipt's existing outstanding debt.
• The Board of Directors unanimously approved the Arrangement Agreement and recommends shareholders vote in favor of the transaction.
• The transaction is not subject to any financing condition, with Kingswood providing an equity commitment letter.
• Upon completion, Quipt will become a privately held company, delisted from The Nasdaq Capital Market and the Toronto Stock Exchange, and deregistered under the Securities Exchange Act of 1934.
• Outstanding Company Options and Restricted Share Units (RSUs) will be cashed out based on the US$3.65 per share price, less exercise price for options and applicable taxes.
• Directors and executive officers of Quipt, holding approximately 11.4% of outstanding shares, and Forager Fund, L.P., holding approximately 9.5% of outstanding shares, have entered into voting support agreements, totaling approximately 20.9% of outstanding shares.

Sentiment

Score: 8

Explanation: The acquisition offers a substantial premium to shareholders, providing immediate liquidity and certainty of value, backed by unanimous board approval and fairness opinions. The transition to a private entity with plans for M&A expansion and investment suggests a strong strategic outlook, despite the loss of public market upside.

Positives

• Shareholders will receive US$3.65 per share in cash, providing immediate liquidity and certainty of value.
• The purchase price represents a 162% premium to Quipt's unaffected stock price on May 19, 2025, the last full trading day prior to the public disclosure of Forager's $3.10 per share proposal.
• The price also represents a 54% premium to Quipt's 30-day Volume Weighted Average Price (VWAP) as of December 12, 2025.
• The transaction has been unanimously approved by Quipt's Board of Directors, which also recommends shareholders vote in favor.
• Fairness opinions were provided by Truist Securities, Inc. and Evans & Evans, Inc., supporting the financial fairness of the consideration.
• The transaction is not subject to any financing condition, backed by an equity commitment letter from Kingswood.

Negatives

• Quipt will cease to be a publicly traded company, removing future public market upside potential for current shareholders.
• Current shareholders will lose direct exposure to Quipt's future growth as a standalone entity.
• A termination fee of $6,950,000 is payable by Quipt under certain circumstances, such as if a superior proposal is accepted.

Risks

• The transaction is subject to the approval of 66% of the votes cast by shareholders and, if required by Canadian securities laws, a simple majority excluding certain votes.
• Court approval of the Arrangement (Interim and Final Orders) is required.
• The accuracy of representations and warranties and compliance with covenants are conditions to closing.
• Dissent rights exercised by shareholders must not exceed 10% of the issued and outstanding shares.
• The absence of a Material Adverse Effect on Quipt is a condition to closing.
• Receipt of approval or expiration of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Approval) is required.
• Risks related to the satisfaction or waiver of the conditions to closing in the anticipated timeframe or at all, including the possibility that the proposed transaction does not close.
• The response of business partners and competitors to the announcement of the proposed transaction.
• Potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction.
• Significant transaction costs.
• Unknown liabilities and the risk of litigation and/or regulatory actions related to the proposed transaction.
• General risks discussed in Quipt's Annual Report on Form 10-K for the year ended September 30, 2025, including those related to credit, market, liquidity, operational, reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy.

Future Outlook

Quipt will transition to a privately held company, with the new owners, Kingswood and Forager, planning to 'reignite the M&A engine' to expand in strategic markets. They also intend to continue investing in people, technology, and best-in-class clinical care, suggesting a focus on operational enhancement and growth through acquisitions.

Management Comments

• "The Board has consistently demonstrated its commitment to maximizing shareholder value, and we believe this transaction achieves that objective by providing substantial and assured value to our shareholders." Greg Crawford, Chairman and Chief Executive Officer of Quipt.
• "I extend my sincere gratitude to the entire Quipt team; your dedication, compassion, and drive have been fundamental to all our accomplishments. Looking forward, the future is exceptionally promising, with Quipt’s established legacy of outstanding in-home respiratory care poised for even greater growth in the future." Greg Crawford.
• "Quipt has built a high quality, scaled respiratory care platform defined by its patient-centric care model, durable referral relationships, and attractive recurring revenue base. We are excited to partner with Greg Crawford, Hardik Mehta, and the entire Quipt team to support the Company’s next chapter of growth as a privately held company. We look forward to reigniting the M&A engine to expand in strategic markets, while continuing to invest in people, technology, and best-in-class clinical care." Kingswood Partner Michael Niegsch and Forager Partner Johnny Wilhelm.

Industry Context

This acquisition reflects a trend of private equity firms consolidating companies within the U.S. home medical equipment and respiratory care market. The focus on a 'patient-centric care model' and 'durable referral relationships' highlights key value drivers in this sector. The stated intention to 'reignite the M&A engine' suggests that the new private owners anticipate further consolidation and expansion opportunities within the industry, potentially through strategic acquisitions to enhance market presence and service offerings.

Management Changes

Corporate Governance

Legal Proceedings

• The filing notes a general risk of litigation and/or regulatory actions related to the proposed transaction.
• Quipt is obligated to defend any proceedings challenging the Arrangement or the Agreement.

Related Party Transactions

• The Purchasers (1567208 B.C. LTD and REM Aggregator, LLC) are entities affiliated with Kingswood Capital Management, LP and Forager Capital Management, LLC.
• Forager Fund, L.P., an affiliate of Forager Capital Management, LLC, holds approximately 9.5% of Quipt's outstanding shares and has entered into a voting support agreement.
• Directors and executive officers of Quipt, including Gregory Crawford and Hardik Mehta, holding approximately 11.4% of outstanding shares, have entered into voting support agreements.

Stakeholder Impact

• Shareholders: Will receive immediate cash liquidity at a significant premium, but will no longer participate in Quipt's future growth as a public entity.
• Employees: Management comments suggest continued investment in people, technology, and clinical care, but the transition to private ownership may lead to organizational restructuring or changes in leadership.
• Customers: The new owners' stated intent to invest in technology and clinical care could lead to enhanced services and offerings for customers.
• Suppliers/Creditors: The transaction includes Quipt's existing debt, and the new owners' plans for M&A expansion could alter existing supplier relationships or create new business opportunities.

Next Steps

• Quipt will apply to the Court for an Interim Order.
• Quipt will prepare, file, and mail a management information circular and proxy statement (Circular) to shareholders.
• A special meeting of shareholders (Meeting) will be called to approve the transaction, requiring 66% of votes cast and a simple majority excluding certain votes.
• Court approval of the Arrangement (Final Order) is required.
• Expiration or termination of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Approval) is required.
• The closing of the Arrangement is expected in the first half of 2026.
• Upon closing, Quipt Shares will be delisted from The Nasdaq Capital Market and the Toronto Stock Exchange.
• Quipt will be deregistered under the Securities Exchange Act of 1934 and cease to be a Canadian reporting issuer.
• The Purchaser intends to reignite the M&A engine to expand in strategic markets and continue investing in people, technology, and clinical care.

Key Dates

Recommendation

The acquisition offers a substantial premium of 162% over the unaffected stock price and 54% over the 30-day VWAP, providing immediate and certain value to shareholders. The unanimous board approval, fairness opinions, and the absence of a financing condition significantly de-risk the transaction for investors. While it removes future public market upside, the immediate cash premium makes it a compelling 'strong buy' for current holders or those looking for a quick arbitrage opportunity, assuming the deal closes as expected.

Keywords

Quipt Home Medical, Acquisition, Kingswood Capital Management, Forager Capital Management, Merger, Home Medical Equipment, Respiratory Care, SEC Filing, 8-K, Plan of Arrangement, Shareholder Value, Delisting, Deregistration, Private Equity